Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Loss and Comprehensive Loss

v3.21.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenue
Expenses:    
Research and development 29,288 16,835
General and administrative 26,480 10,022
Operating expenses 55,768 26,857
Other income :    
Interest income 522 574
Foreign exchange gain 8 6
Total other income 530 580
Net loss (55,238) (26,277)
Other comprehensive loss:    
Unrealized gain/(loss) on securities available-for-sale (18) 18
Total comprehensive loss $ (55,256) $ (26,259)
Basic and diluted loss per common share (in dollars per share) $ (0.67) $ (0.52)
Weighted average number of common shares outstanding used in the calculation of (in thousands)    
Basic and diluted loss per common share (in shares) 81,837 50,160